Abstract
IntroductIon
Rectal cancer accounts for a third of patients with large bowel cancer [1, 2] . Historically, management of rectal cancers has been of variable standard with significant differences in local recurrence rates [3] [4] [5] [6] . The Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the National Institute for Health and Care Excellence (NICE) have both recommend that rectal cancer should be managed by a multi-disciplinary team (MDT) [7, 8] . This has led to initiatives to standardize MDT practises across the country.
Currently, nearly 90% of patients with colorectal cancer undergo discussion and treatment planning at an MDT in the United Kingdom [2] . Total mesorectal excision (TME) has been established as the gold standard for the management of mid and lower rectal cancers over the last few years following the results of numerous trials such as the MR CR07 and Dutch TME trials [5, 6, 9] . The role of neo-adjuvant therapy is also well established in patients with threatened margins [7, 8] .
We have had an established MDT team managing colorectal cancer since 1997. Our unit has been performing laparoscopic rectal resection under the auspices of the MDT since 2000, initially in selected cases and since 2008, with increased experience, as the default approach. NICE recommends laparoscopic rectal resection by experienced surgeons [10] . We undertook this retrospective analysis of a prospectively maintained database to assess the effectiveness of our MDT rectal cancer management outcomes.
MAtErIALS And MEtHodS

Definitions
Rectal cancer = All cancers ≤ 15 cm from anal verge as measured during rigid sigmoidoscopic examination were classified as rectal cancers. These were further categorized as below: Lower rectal cancer (LRC) = All palpable tumours (≤ 6 cm from anal verge); upper rectal cancer (URC) = All other tumours (6-15 cm from anal verge); Circumferential resection margin (CRM) positivity = if CRM < 1 mm (Both on pre-op MRI and at histopathology); Local or distant metastasis was defined on the basis of radiological evidence.
MDT
Our MDT consists of 3 colorectal surgeons, 1 specialist GI clinical oncologist, 2 specialist radiologists, 1 pathologist, 1 colorectal specialist nurse, 1 enhanced recovery coordinator, 2 enterostomal therapists, 1 palliative care consultant/specialist nurse and 2 gastroenterologists. This team meets every week and has been active since 1997 with a track record of publications, awards and innovative solutions to enhancing quality of care and patient experiences [11] [12] [13] . Non clinical business meetings of the team are held to facilitate the formulation and agreement of local protocols for colorectal cancer diagnosis, investigations and treatment.
Staging
All patients diagnosed with rectal cancer were staged with a computerized tomography (CT) scan of thorax, abdomen and pelvis. They also underwent either a colonoscopy or a CT colonogram (done as a part of staging CT). All patients with LRC and some with URC underwent a magnetic resonance imaging (MRI) of rectum for local staging as per the T2 weighted fast spin echo protocol, in 5 mm slices in the axial, coronal and sagittal planes in addition to oblique axials targeted at right angles to the axis of the tumour, using 3 mm slices and smaller "Field of View" for maximal resolution. As per common practice in the United Kingdom, none of our patients underwent endo-rectal ultrasound scanning.
Treatment planning
The staging investigations of all patients were reviewed by the MDT and treatment plans formulated according to the MDT protocol (Figure 1 ). Patients with threatened CRM were offered neo-adjuvant therapy (NAT) given as a pre-operative Long Course Chemo-Radiotherapy (LCRT), 45 Gy in 25 fractions to the pelvis over 5 wk with concurrent Capecitabine chemotherapy. In addition, short course radiotherapy 25 Gy in 5 fractions over 1 wk was considered in patients with moderate risk rectal cancers. The patients were then restaged and reviewed at MDT prior to surgery. Cases considered suitable for resection were scheduled for surgery 6-10 wk following NAT.
All patients with URC were planned for an anterior resection (AR). Planned surgical options for patients with LRC were either total mesorectal excision with defunctioning ileostomy (TME + I) or when the sphincters or levators were threatened, an abdomino-perineal excision (APER).
Post-operative histology was reviewed by the MDT and clinically fit patients with poor prognostic features on histology were offered adjuvant treatment (AT) with Oxaliplatin and 5 fluorouracil based combination chemo therapy.
Surgical procedure
The default surgical approach was laparoscopic resection except when the patient had had multiple previous surgery, anaesthetic considerations precluded a laparoscopic approach and occasionally due to technical issues such as particularly obese male patients with bulky tumours not responsive to neo-adjuvant treatment. We defined conversion as previously published [12] : (1) If the final incision made was longer than planned pre operatively; (2) If the incision needed to be made at an earlier stage of the operation than planned preoperatively; and (3) If the incision was made at a site other than that planned pre-operatively.
All laparoscopic procedures were performed by one of two consultant surgeons (each with experience of over 100 colorectal resections at the beginning of the study period) or by senior trainees under direct supervision (consultant scrubbed). All procedures were performed with the patient in the Lloyd Davies position with steep Trendelenburg tilt, following a step-wise approach (Table  1 ) [14, 15] . The open procedures and the converted cases followed a similar step-wise approach through a midline laparotomy.
Follow-up protocol
All patients were reviewed initially at 6 wk after their surgery. The follow up protocol was a 6 monthly clinical review with haematological and biochemical tests including tumour marker CEA for 5 years, an annual CT scan of thorax, abdomen and pelvis for 3 years and a surveillance colonoscopy at 3 and 6 years. The length of follow-up was recorded in months from the date of operation.
Patients included in this study
After appropriate institutional approvals, all patients with rectal cancer discussed at our MDT meeting between Jan 2008 and Jan 2011 were identified and the patient demographics, treatment, post-operative histology and follow-up data were studied.
Outcome measures
The primary outcome measures of the study were local recurrence rates and disease free survival. The secondary outcome measures included post-operative length of stay, major complications and overall survival.
statistical analysis
The data was analysed in terms of frequencies and percentages. Significance of any differences were analysed using χ 2 test. A Kaplan-Meier analysis was performed for overall survival and disease free survival. with rectal cancer. Of these, there were 2 patients with locally advanced disease invading prostate and so were referred for exenteration elsewhere. A further 6 patients went on to have palliative treatment due to either advanced presentation or significant medical comorbidities. The remaining 133 patients were staged as suitable for potentially curative resections. Of these, 72 (54%) were upper rectal tumours (URC) and 61 (46%) were lower rectal tumours (LRC). Three (2%) patients had resectable metastases at diagnosis and were treated with primary rectal resection, followed by chemotherapy and surgery for metastases.
The pre-operative (putative) CRM was threatened in 19 (14%) patients (4 patients due to presence of nodes close to the CRM). Of these, 14 patients had LCRT; 1 had short course radiotherapy (25 Gy in 5 fractions over 1 wk). Four patients did not receive any Neoadjuvant therapy: 1 female patient with an anterior tumour where there was lack of consensus on preoperative staging being T2 vs T4 and 3 patients where there was a small node of doubtful significance threatening the margin.
Interval between completion of NAT and surgery was a median 10 (6-24) wk. One patient had a radiological complete response to neo-adjuvant therapy and opted initially for a watch and wait policy prior to eventually opting to receive surgery. Table 2 summarizes the operations performed. All 72 patients with URC underwent an AR. Of the 61 with LRC, 29 had TME + I, 1 patient had a TME Hartmann's procedure and 27 had APER. Four patients had TME and anastomosis without covering ileostomy. Surgery following NAT was either APER (8/15) or TME + I (7/15).
Laparoscopic resection was attempted in 118/133 (89%). Conversion rate was 5% (6 out of 118 patients).
The reasons for conversion were uncontrollable bleeding from the IM pedicle (n = 1), low tumour in a male pelvis, requiring a suprapubic incision rather than the planned left iliac fossa incision for specimen delivery (n = 1) and dense adhesions (n = 4), requiring incisions either larger than planned or at an earlier stage of the operation). The remaining 15 patients (11%) underwent a planned open procedure due to previous extensive surgery, locally advanced tumour in an android pelvis or poor response to LCRT.
Median post-operative length of stay was 5 d (3-49). Major complications needing re-operation within 30 d occurred in 8 (6%) patients [Anastomotic leak: 2, Pelvic haemorrhage requiring packing: 2, Small Bowel Obstruction: 2 (1 -port site; 1 -pelvic), Intra-abdominal collection: 1, Wound dehiscence: 1].
Post-operative histology is shown in Table 3 . One hundred and twenty four patients (93.3%) had R0 resection and 9 (6.7%) had an R1 resection (CRM positive -6 due to tumour, 3 due to nodes). There were no R2 resections in this cohort. Median LN harvest was 12 for the laparoscopic group and 10 for the open group (p < 0.01). Of the 9 patients with positive CRM 4 were URC Left iliac fossa port extended as a transverse incision for specimen delivery; protect wound and deliver specimen by the stapled end 13
Complete mesenteric ligation, proximal bowel division and prepare proximal bowel for anastomosis 14
Close wound, re-establish pneumoperitoneum 15
Intra-corporeal bowel anastomosis with no tension, no twist and vital structures protected 16 Close incisions 1 In patients undergoing laparoscopic abdomino-perineal excision, the left sided port is placed at the site of the planned colostomy and the laparoscopic dissection stopped at the mid rectal level, the proximal colon divided intra-corporeally with a stapler and proceed to a wide excision of the anal sphincter complex to obtain a cylindrical specimen. and 5 were LRC. The pre-operative MRI had accurately predicted this in all 5 LRC patients, 4 of whom had received NAT. None of the URCs had had pre-operative MRI as per our practice at that time and so could not be predicted and they did not receive any NAT. Fifty-six patients had adverse features on histology making them eligible for adjuvant therapy (AT). Of these, 13 were unfit and 3 declined the offer of further chemotherapy. The remaining 40 patients underwent AT.
Median follow up was for 53 mo (0-82). Long-term complications occurred in 9 (6.7%) patients (parastomal hernia: 6, port site hernia: 1, anastomotic stricture: 1, late onset left ureteric obstruction due to fibrosis: 1).
The 90-d mortality was 1.5% (2 patients: 1 in-hospital due to anastomotic leak; 1 patient post discharge -cause unknown). Disease related mortality over the follow-up period was 11 (8.2%); however, overall mortality for the follow-up period was 39 (29.3%).
Four patients (3%) had local recurrence. The durations to development of local recurrence were 15, 23, 33 and 39 mo. On further analysis of the sub-group with local recurrence, only 1 patient had had a histologically positive CRM. This patient had an upper rectal tumour and had not been considered for NAT. The other 3 patients having local recurrence were all T3 URC and all had had a R0 resection with CRM clearance of between 1-2 mm. In this cohort, we had no local recurrence in any patients with LRC.
Twenty two patients (16.5%) developed distant metastases and one patient developed metachronous colonic cancer. Four of these had no poor prognostic factors on histology such as node positive disease, extra-mural lympho-vascular invasion and/or poor differentiation. Of the 18 with poor prognostic markers, 3 had declined and 5 had been deemed unfit for AT. Figure 2 shows the Kaplan Meier curve for our cohort.
dIScuSSIon
Patients in our unit have been receiving care under the MDT umbrella since 1997. Our unit has a relatively high uptake of laparoscopic rectal resections with 89% undergoing laparoscopic resection with a relatively low conversion rate using strict definitions for conversion. The median length of stay was 5 d and is comparable to most enhanced recovery programmes. Oncological results too are acceptable with a CRM positivity rate of 4% for sphincter saving resections (4 out of 106 patients) and 18% for APER (5 out of 27 patients). LNH was higher following laparoscopic resection, in keeping with other studies [16] . MDT management is a concept propagated by practice with no "research/trial" based evidence. There is no level 1 evidence that supports MDT, no grade of recommendation is provided for its use in national guidelines and yet, this concept is gaining acceptance worldwide. MDT management has been a mandatory requirement for treatment of cancers in United Kingdom since 2000. For this reason, we cannot perform a meaningful comparative analysis of patients who have not received care under the MDT umbrella. The management of the rectal cancer has also undergone a significant change over this period. This precludes use of a historical cohort for comparison as there could be other confounding factors that influence outcomes.
We believe that this the first observational study attempting to clarify the role of various MDT members who make individual specialist contributions, based on 0  T1  14  T2  42  T3  58  T4  17  N0  85  N1  31  N2  15 consensual decisions arrived at by a group of experts, resulting in improved clinical effectiveness. Lap TME has been shown to be safe with acceptable short-term clinical and oncological outcomes [5, [17] [18] [19] . The 2 most recent trials, ALaCaRT and the ACOSOG Z6051, have not been able to demonstrate the non-inferiority of laparoscopic resections compared to open resections in terms "completeness of excision" using a composite scoring system [20, 21] . However, they are still accruing data on long term oncological outcomes. Laparoscopic TME can be technically challenging and should be undertaken by experienced surgeons [12, [20] [21] [22] . Caution should therefore be exercised when evaluating results of laparoscopic TME when the expertise of the surgeons has not been defined. The senior surgeons have had a mean experience of 6 years between them with over 100 laparoscopic resections each prior to the commencement of this study. From this study, we see that acceptable long-term oncological results can be safely achieved when laparoscopic approach is pragmatically applied by appropriately trained surgeons in the context of multimodal therapy overseen by MDT.
The few RCTs reporting 5 year survival were not specifically designed or powered for long term outcomes [3] . More recently several meta-analyses published have not come up with any strong conclusions either way with respect to long-term survival [3, 4, 19, 23, 24] . However, laparoscopic resection seems to be associated with a lower local recurrence rate [24] . This lack of clarity has been the cause for variable uptake of Lap TME ranging from 0%-100% [2, 25] . We believe that this study is one of the first to report on outcomes of laparoscopic rectal resections outside of RCTs or case control studies. Tables 4 and  5 show our results which compare favourably to other published studies. Figure 2 shows the Kaplan Meier curves for our cohort which shows an overall survival of 81% and disease free survival of 90% at median follow-up. This compares favourably with other series with similar follow-up which have reported a predicted overall survival of 81% and disease free survival of 70% [26] . Our survival figures show that our cohort of patients were more likely to die from other causes than from disease recurrence, in keeping with the high comorbidity of our catchment population [27] , most of which falls within the highest quintile of the deprivation index in the United Kingdom.
A 12-year follow-up of Dutch TME trial cohort showed local recurrence of 6.5% (68 patients) in 1082 patients who had an R0 resection [28] . In comparison, we observed a local recurrence rate of 2.4% (3 patients) in 124 patients having an R0 resection. All recurrences were in patients with URC with no recurrences in LRC. We observed only 1 local recurrence in 9 patients who had an R1 resection (11.1%). However extrapolating similar data from the Dutch TME trial would give a figure of 20.8% patients with involved margins developing a local recurrence. This comparison however, may be misleading as the follow up in our study (53 mo) is shorter than the Dutch TME trial (12 years).
Traditionally, local recurrence after rectal cancer resection usually presents within 2 years [2, 28] . In our series, we have had a median follow up of 53 mo and have not noticed any local recurrence in the LRC group. The followup of the Dutch TME trial cohort confirmed that pre-operative radiotherapy not only reduced local recurrence but was especially effective in preventing anastomotic recurrences [28] . The same effect probably accounts for the absence of local recurrence noted in our study for the low rectal cancers in spite of 10% (6 of 61 LRC) CRM positivity. Another hypothesis worth considering could be that CRM positivity due to lymph nodes may carry a lesser risk of local recurrence when compared with cases where the CRM was involved by the primary tumour.
We believe this observed low rate of local recurrence is due to effective working within a well-established specialist MDT, resulting in appropriate use of NAT for our cohort of patients.
In conclusion, this study demonstrates that good long term oncological outcomes can be achieved for patients with rectal cancer when appropriate multi-disciplinary expertise is combined with surgery being performed by adequately trained surgeons. Neo-adjuvant chemoradiotherapy improves the oncological outcomes without precluding the routine use of the laparoscopic approach to rectal resection.
coMMEntS
Background
Rectal cancer accounts for a third of patients with large bowel cancer. Historically, management of rectal cancers has been of variable standard with significant differences in local recurrence rates. The Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the National Institute for Health and Care Excellence (NICE) have both recommend that rectal cancer should be managed by a multi-disciplinary team (MDT). This has led to initiatives to standardize MDT practises across the country. The authors undertook this retrospective analysis of a prospectively maintained database to assess the effectiveness of the MDT rectal cancer management outcomes.
Table 4 Comparison of circumferential resection margin positive
Type of operation Dutch TME trial [6] CLASICC trial [5] MR CRO7 trial [9] Our series Sphincter saving resection 13% 10% 8% 3% (4/106) APER 29% 21% 17% 18% (5/27) TME: Total mesorectal excision; APER: Abdomino-perineal excision.
coMMEntS Table 5 Comparison of local recurrence Meta-analysis [4] (n = 1544) Dutch TME trial [6] (n = 1586) CLASICC trial [5] (n = 400) MRC CR07 trial [9] (n = 1350) Our series (n = 133)
Local recurrence 13% 8% 6.80% 7% 3% (4/133) TME: Total mesorectal excision.
